Chih-Hsin Yang J, Liu G, Lu S, He J, et al. Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. J Thorac Oncol 2023 Aug 11:S1556-0864(23)00730.
PMID: 37574132